Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Polymorphisms in the P450 c17 (17-hydroxylase/17, 20-Lyase) gene: association with estradiol and testosterone concentration in hypospadias.

Yadav CS, Bajpai M, Kumar V, Datta SK, Gupta P, Ahmed RS, Banerjee BD.

Urology. 2011 Oct;78(4):902-7. doi: 10.1016/j.urology.2011.04.021. Epub 2011 Jun 15.

PMID:
21676446
2.

[Association between polymorphism of CYP17 gene and serum hormone concentrations in aged men].

Wang JQ, Gu X, Chen JC, Sun XQ, Mu HT, Wei ZH, Li M, Xin DQ, Na YQ.

Zhonghua Nan Ke Xue. 2005 Jun;11(6):442-4. Chinese.

PMID:
15999490
3.

Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.

Samtani R, Bajpai M, Vashisht K, Ghosh PK, Saraswathy KN.

J Urol. 2011 Jun;185(6):2334-9. doi: 10.1016/j.juro.2011.02.043. Epub 2011 Apr 21.

PMID:
21511288
4.

The relationship between müllerian inhibiting substance and androgens in boys with hypospadias.

Austin PF, Siow Y, Fallat ME, Cain MP, Rink RC, Casale AJ.

J Urol. 2002 Oct;168(4 Pt 2):1784-8; discussion 1788.

PMID:
12352359
5.

CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.

Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S.

J Hum Genet. 2007;52(2):159-65. Epub 2007 Jan 18.

PMID:
17235448
6.

Polymorphisms in steroidogenesis genes, sex steroid levels, and high myopia in the Taiwanese population.

Chen ZT, Wang IJ, Liao YT, Shih YF, Lin LL.

Mol Vis. 2011;17:2297-310. Epub 2011 Aug 25.

7.

Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement.

Schatzl G, Gsur A, Bernhofer G, Haidinger G, Hinteregger S, Vutuc C, Haitel A, Micksche M, Marberger M, Madersbacher S.

Urology. 2001 Mar;57(3):567-72.

PMID:
11248649
8.

Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey.

Yilmaz MB, Pazarbasi A, Guzel AI, Kocaturk-Sel S, Kasap H, Kasap M, Urunsak IF, Basaran S, Alptekin D, Demirhan O.

Genet Mol Res. 2011 Sep 9;10(3):1999-2008. doi: 10.4238/vol10-3gmr1204.

9.

CYP17 and COMT gene polymorphisms can influence bone directly, or indirectly through their effects on endogenous sex steroids, in postmenopausal Japanese women.

Gorai I, Inada M, Morinaga H, Uchiyama Y, Yamauchi H, Hirahara F, Chaki O.

Bone. 2007 Jan;40(1):28-36. Epub 2006 Sep 12.

PMID:
16971197
10.

Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women.

Somner J, McLellan S, Cheung J, Mak YT, Frost ML, Knapp KM, Wierzbicki AS, Wheeler M, Fogelman I, Ralston SH, Hampson GN.

J Clin Endocrinol Metab. 2004 Jan;89(1):344-51.

PMID:
14715870
11.

Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.

Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, Chen CJ.

J Natl Cancer Inst. 2001 Nov 7;93(21):1644-51.

PMID:
11698569
12.

Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5'-UTR in patients with polycystic ovarian syndrome.

Marszalek B, Laciński M, Babych N, Capla E, Biernacka-Lukanty J, Warenik-Szymankiewicz A, Trzeciak WH.

Gynecol Endocrinol. 2001 Apr;15(2):123-8.

PMID:
11379008
13.

CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

Verla-Tebit E, Wang-Gohrke S, Chang-Claude J.

Breast Cancer Res. 2005;7(4):R455-64. Epub 2005 Apr 12.

14.

CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer.

Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR.

Breast Cancer. 2004;11(4):380-8.

PMID:
15604994
15.

A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.

Sata F, Yamada H, Yamada A, Kato EH, Kataoka S, Saijo Y, Kondo T, Tamaki J, Minakami H, Kishi R.

Mol Hum Reprod. 2003 Nov;9(11):725-8.

PMID:
14561815
16.
17.

CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.

Tüzüner BM, Oztürk T, Kisakesen HI, Ilvan S, Zerrin C, Oztürk O, Isbir T.

In Vivo. 2010 Jan-Feb;24(1):71-4.

PMID:
20133979
18.
19.

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

Lunn RM, Bell DA, Mohler JL, Taylor JA.

Carcinogenesis. 1999 Sep;20(9):1727-31.

PMID:
10469617
20.

The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.

Ye Z, Parry JM.

Mutagenesis. 2002 Mar;17(2):119-26.

PMID:
11880540

Supplemental Content

Support Center